chevron_leftBack
As of 24 April 2025, Allergy Therapeutics plc has a market cap of $398.41M USD, ranking #13227 globally and #322 in the United Kingdom. It ranks #1297 in the Healthcare sector, and #315 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$398.41MUSD
300.29M GBP
Enterprise Value
$428.71MUSD
323.13M GBP
Revenue (TTM)
$73.84MUSD
55.66M GBP
EBITDA (TTM)
-$35.22MUSD
-26.55M GBP
Net Income (TTM)
-$47.3MUSD
-35.65M GBP
EBITDA Margin
-48%
Profit Margin
-64%
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Manuel Llobet
open_in_new
Employees
612
Founded
1998
Website
allergytherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.4% | 5.3% | -12% | -19% | 23% | 111% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
AGY
Allergy Therapeutics PLC
ISIN: GB00B02LCQ05
Shares Out.:
Shares Outstanding:
4.766B1
Shares Float:
179.442M2
|
6 GBX | |
|
AGYTF
Allergy Therapeutics PLC
ISIN: GB00B02LCQ05
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0820 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
